RGC
Regencell Bioscience Holding
NASDAQ · Pharmaceuticals
$27.23
+2.16 (+8.62%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.66B | 3.76B | 3.59B |
| Net Income | 706.46M | 788.49M | 815.65M |
| EPS | — | — | — |
| Profit Margin | 19.3% | 21.0% | 22.7% |
| Rev Growth | +1.6% | +15.1% | +20.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.48B | 2.80B | 2.81B |
| Total Equity | 10.84B | 10.07B | 9.12B |
| D/E Ratio | 0.23 | 0.28 | 0.31 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.06B | 1.04B | 1.04B |
| Free Cash Flow | 809.03M | 638.27M | 648.55M |